0001828182-22-000041.txt : 20220531 0001828182-22-000041.hdr.sgml : 20220531 20220531172352 ACCESSION NUMBER: 0001828182-22-000041 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220531 DATE AS OF CHANGE: 20220531 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Signify Health, Inc. CENTRAL INDEX KEY: 0001828182 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40028 FILM NUMBER: 22984802 BUSINESS ADDRESS: STREET 1: 800 CONNECTICUT AVENUE CITY: NORWALK STATE: CT ZIP: 06854 BUSINESS PHONE: (203) 541-4600 MAIL ADDRESS: STREET 1: 800 CONNECTICUT AVENUE CITY: NORWALK STATE: CT ZIP: 06854 10-Q/A 1 sgfy-20220331.htm 10-Q/A sgfy-20220331
0001828182TRUEQ12022--12-3100018281822022-01-012022-03-310001828182us-gaap:CommonClassAMember2022-05-27xbrli:shares0001828182us-gaap:CommonClassBMember2022-05-27



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from     to    .
Commission File Number: 001-40028
Signify Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware
(State or Other Jurisdiction of
Incorporation or Organization)
85-3481223
(I.R.S. Employer
Identification Number)
800 Connecticut Avenue, Norwalk, CT 06854
(Address of principal executive offices)
(203) 541-4600
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Class A common stock, par value $0.01 per ShareSGFYNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company
☐
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Yes ☐ No ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
As of May 27, 2022, there were 176,364,619 outstanding shares of Class A common stock, $0.01 par value, and 57,515,043 outstanding shares of Class B common stock, $0.01 par value.




EXPLANATORY NOTE

The purpose of this Amendment (the “Amendment”) to our Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”), as filed with the Securities and Exchange Commission (the “SEC”) on May 5, 2022, is solely to correct an inadvertent omission of certain language from paragraph 4 of the Exhibit 31.1 and Exhibit 31.2 certifications originally filed with our Form 10-Q.

This Amendment contains only the Cover Page, this Explanatory Note and Exhibits 31.1 and 31.2. No other changes have been made to the Form 10-Q as filed with the SEC on May 5, 2022. This Amendment speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q. Accordingly, this Amendment should be read in conjunction with the Form 10-Q and our other filings with the SEC.




Item 6. Exhibits.
The exhibits listed in the index below are filed or incorporated by reference as a part of this Amendment to the Quarterly Report on Form 10-Q.
31.1*
31.2*
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema Document
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*XBRL Taxonomy Extension Label Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document
101*The following financial information from the Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Changes in Members’ Equity, (iv) the Condensed Consolidated Statements of Cash Flows and (v) the Notes to the Condensed Consolidated Financial Statements
104*Cover Page Interactive Data File – The cover page from this Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 is formatted in iXBRL (included as Exhibit 101)
  
 
*    Filed or furnished herewith


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SIGNIFY HEALTH, INC.
Date: May 31, 2022By:/s/ Kyle Armbrester
Kyle Armbrester
Chief Executive Officer
Date: May 31, 2022By:/s/ Steven Senneff
Steven Senneff
President, Chief Financial and Administrative Officer


4
 EX-31.1 2 exhibit311033122a.htm EX-31.1 Document

Exhibit 31.1
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Kyle Armbrester, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Signify Health, Inc;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 31, 2022/s/ Kyle Armbrester
 Kyle Armbrester
 Chief Executive Officer

 EX-31.2 3 exhibit312033122a.htm EX-31.2 Document

Exhibit 31.2
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Steven Senneff, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Signify Health, Inc;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Date: May 31, 2022/s/ Steve Senneff
 Steven Senneff
 President, Chief Financial and Administrative Officer

 EX-101.SCH 4 sgfy-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 sgfy-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 sgfy-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Interactive Data Current Entity Interactive Data Current Document Transition Report Document Transition Report Document Period End Date Document Period End Date Class B Common Stock Common Class B [Member] Entity Central Index Key Entity Central Index Key Document Information [Table] Document Information [Table] Entity Ex Transition Period Entity Ex Transition Period Entity Filer Category Entity Filer Category Document Quarterly Report Document Quarterly Report Entity Emerging Growth Company Entity Emerging Growth Company Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Entity Current Reporting Status Entity Current Reporting Status Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amendment Description Amendment Description Entity Registrant Name Entity Registrant Name Entity Small Business Entity Small Business Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province City Area Code City Area Code Entity Shell Company Entity Shell Company Document Type Document Type Document Information [Line Items] Document Information [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus Class of Stock [Domain] Class of Stock [Domain] Class A Common Stock Common Class A [Member] Cover [Abstract] Entity Address, City or Town Entity Address, City or Town Class of Stock [Axis] Class of Stock [Axis] Entity File Number Entity File Number Amendment Flag Amendment Flag Trading Symbol Trading Symbol Entity Tax Identification Number Entity Tax Identification Number Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Period Focus EX-101.PRE 7 sgfy-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2022
May 27, 2022
Document Information [Line Items]    
Document Type 10-Q/A  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-40028  
Entity Registrant Name Signify Health, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-3481223  
Entity Address, Address Line One 800 Connecticut Avenue  
Entity Address, City or Town Norwalk  
Entity Address, State or Province CT  
Entity Address, Postal Zip Code 06854  
City Area Code 203  
Local Phone Number 541-4600  
Title of 12(b) Security Class A common stock, par value $0.01 per Share  
Trading Symbol SGFY  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Central Index Key 0001828182  
Amendment Flag true  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Amendment Description EXPLANATORY NOTEThe purpose of this Amendment (the “Amendment”) to our Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”), as filed with the Securities and Exchange Commission (the “SEC”) on May 5, 2022, is solely to correct an inadvertent omission of certain language from paragraph 4 of the Exhibit 31.1 and Exhibit 31.2 certifications originally filed with our Form 10-Q.This Amendment contains only the Cover Page, this Explanatory Note and Exhibits 31.1 and 31.2. No other changes have been made to the Form 10-Q as filed with the SEC on May 5, 2022. This Amendment speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q. Accordingly, this Amendment should be read in conjunction with the Form 10-Q and our other filings with the SEC.  
Class A Common Stock    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   176,364,619
Class B Common Stock    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   57,515,043
XML 9 sgfy-20220331_htm.xml IDEA: XBRL DOCUMENT 0001828182 2022-01-01 2022-03-31 0001828182 us-gaap:CommonClassAMember 2022-05-27 0001828182 us-gaap:CommonClassBMember 2022-05-27 shares 0001828182 true Q1 2022 --12-31 10-Q/A true 2022-03-31 false 001-40028 Signify Health, Inc. DE 85-3481223 800 Connecticut Avenue Norwalk CT 06854 203 541-4600 Class A common stock, par value $0.01 per Share SGFY NYSE Yes Yes Non-accelerated Filer false true false false 176364619 57515043 EXPLANATORY NOTEThe purpose of this Amendment (the “Amendment”) to our Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”), as filed with the Securities and Exchange Commission (the “SEC”) on May 5, 2022, is solely to correct an inadvertent omission of certain language from paragraph 4 of the Exhibit 31.1 and Exhibit 31.2 certifications originally filed with our Form 10-Q.This Amendment contains only the Cover Page, this Explanatory Note and Exhibits 31.1 and 31.2. No other changes have been made to the Form 10-Q as filed with the SEC on May 5, 2022. This Amendment speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q. Accordingly, this Amendment should be read in conjunction with the Form 10-Q and our other filings with the SEC. EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 3 31 1 false 2 0 false 1 false false R1.htm 0001001 - Document - Cover Page Sheet http://signifyhealth.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports sgfy-20220331.htm exhibit311033122a.htm exhibit312033122a.htm sgfy-20220331.xsd sgfy-20220331_def.xml sgfy-20220331_lab.xml sgfy-20220331_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sgfy-20220331.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "sgfy-20220331_def.xml" ] }, "inline": { "local": [ "sgfy-20220331.htm" ] }, "labelLink": { "local": [ "sgfy-20220331_lab.xml" ] }, "presentationLink": { "local": [ "sgfy-20220331_pre.xml" ] }, "schema": { "local": [ "sgfy-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 38, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 31, "memberCustom": 0, "memberStandard": 2, "nsprefix": "sgfy", "nsuri": "http://signifyhealth.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgfy-20220331.htm", "contextRef": "ib7c6566fb4f0443aa051fb469d80d766_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://signifyhealth.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgfy-20220331.htm", "contextRef": "ib7c6566fb4f0443aa051fb469d80d766_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Class A Common Stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class B [Member]", "terseLabel": "Class B Common Stock" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://signifyhealth.com/role/CoverPage" ], "xbrltype": "stringItemType" } }, "unitCount": 1 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r4": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r5": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r6": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0001828182-22-000041-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001828182-22-000041-xbrl.zip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end